Effects of somatostatin and octreotide on the interactions between neoplastic gastroenteropancreatic endocrine cells and endothelial cells: A comparison between in vitro and in vivo properties

Neuroendocrinology

Volumn 94, Issue 3, 2011, Pages 200-208

  Walter, Thomas ^a,b   Hommell Fontaine, Juliette ^a   Gouysse, Géraldine ^a   Pourreyron, Céline ^a   Nejjari, Mimoun ^a   Villaume, Karine ^a   Causeret, Sylvain ^a   Hervieu, Valérie ^a,b   Poncet, Gilles ^a,b   Roche, Colette ^a   Scoazec, Jean Yves ^a,b  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Angiogenesis; Endocrine tumors; Gastroenteropancreatic endocrine cells; Octreotide; Somatostatin

Indexed keywords

OCTREOTIDE; SOMATOSTATIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER GROWTH; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOCRINE CELL; ENDOTHELIUM CELL; FEMALE; GASTROENTEROPANCREATIC ENDOCRINE CELL; GASTROENTEROPANCREATIC ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MICROTUBULE; MICROVASCULATURE; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL COMMUNICATION; CELLS, CULTURED; ENTEROENDOCRINE CELLS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; OCTREOTIDE; PANCREATIC NEOPLASMS; SOMATOSTATIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81355147677     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000328134     Document Type: Article

References (31)

1. Marion-Audibert AM, Barel C, Gouysse G, Dumortier J, Pilleul F, Pourreyron C, Hervieu V, Poncet G, Lombard-Bohas C, Chayvialle JA, Partensky C, Scoazec JY: Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003; 125: 1094-1104. (Pubitemid 37193456)
2. Christofori G, Naik P, Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995; 9: 1760-1770.
3. Fan L, Iseki S: Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat. Arch Histol Cytol 1998; 61: 17-28. (Pubitemid 28217201)
4. Partanen TA, Arola J, Saaristo A, Jussila L, Ora A, Miettinen M, Stacker SA, Achen MG, Alitalo K: VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000; 14: 2087-2096.
5. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, Sorokin L, Fassler R, Gu G, Gerber HP, Ferrara N, Melton DA, Lammert E: The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell 2006; 10: 397-405.
6. Monnier J, Samson M: Prokineticins in angiogenesis and cancer. Cancer Lett 2010; 296: 144-149.
7. Danesi R, Del Tacca M: The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 1996; 45(suppl 1):49-50.
8. Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D, Barrie R: Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs 1997; 15: 77-86. (Pubitemid 27217753)
9. Garcia de la Torre N, Wass JA, Turner HE: Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57: 425-441. (Pubitemid 35216294)
10. Reubi JC, Horisberger U, Laissue J: High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumor-host interaction? Int J Cancer 1994; 56: 681-688. (Pubitemid 24086771)
11. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991; 50: 245-251.
12. Zalatnai A, Timar F: In vitro antiangiogenic effect of sandostatin (octreotide) on the proliferation of the placental vessels. Anticancer Res 2002; 22: 4225-4227. (Pubitemid 36134462)
13. Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, Bousquet C: Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA 2009; 106: 17769-17774.
14. de Herder WW, Lamberts SW: Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol 2002; 14: 53-57. (Pubitemid 34072964)
15. Cascinu S, Del Ferro E, Ligi M, Staccioli MP, Giordani P, Catalano V, Agostinelli R, Muretto P, Catalano G: Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest 2001; 19: 8-12. (Pubitemid 32233796)
16. Koizumi M, Onda M, Tanaka N, Seya T, Yamada T, Takahashi Y: Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion 2002; 65: 200-206.
17. Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q: Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol 2003; 129: 327-334. (Pubitemid 36963194)
18. Modigliani E, Alamowitch C, Cohen R, Calmettes C, Guliana JM, Franc B, Bernard C, Chayvialle JA: The intratumoral immunoassayable somatostatin concentration is frequently elevated in medullary thyroid carcinoma. Results in 34 cases. Cancer 1990; 65: 224-228. (Pubitemid 20035346)
19. Rindi G, Grant SG, Yangaou Y, Ghatei MA, Bloom SR, Bautch VL, Solcia E, Polak JM: Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice: heterogeneity of hormone expression. Am J Pathol 1990; 136: 1349-1363. (Pubitemid 20210334)
20. Kieffer TJ, Huang Z, McIntosh CH, Buchan AM, Brown JC, Pederson RA: Gastric inhibitory polypeptide release from a tumor-derived cell line. Am J Physiol 1995; 269:E316-E322.
21. Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, Scoazec JY: VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway. Neuroendocrinology 2010; 91: 268-278.
22. Pourreyron C, Poncet G, Roche C, Gouysse G, Nejjari M, Walter T, Villaume K, Jacquier MF, Bernard C, Dumortier J, Chayvialle JA, Bachelot T, Scoazec JY: The role of angiogenesis in endocrine liver metastases: an experimental study. J Surg Res 2008; 144: 64-73. (Pubitemid 350245385)
23. van der Horst-Schrivers ANA, Bruins Slot MHE, Willemse PHB, Kema IP, De Vries EGE, Machteld Wymenga AN: Effect of interferon and 5-fluorouracil on serum VEGF levels in neuroendocrine tumors. Acta Oncol 2008; 47: 153-155.
24. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, Basolo F, Campagni A, Tacca MD: Inhibition of experimental angiogenesis by the somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997; 3: 265-272. (Pubitemid 27107304)
25. Baldysiak-Figiel A, Lang GK, Kampmeier J, Lang GE: Octreotide prevents growth factorinduced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol 2004; 180: 417-424. (Pubitemid 38443394)
26. Lawnicka H, Stepien H, Wyczolkowska J, Kolago B, Kunert-Radek J, Komorowski J: Effect of somatostatin and octreotide on proliferation and vascular endothelial growth factor secretion from murine endothelial cell line (HECa10) culture. Biochem Biophys Res Commun 2000; 268: 567-571. (Pubitemid 30119662)
27. Patel PC, Barrie R, Hill N, Landeck S, Kurozawa D, Woltering EA: Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 1994; 116: 1148-1152. (Pubitemid 24382179)
28. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144: 1574-1584. (Pubitemid 36428500)
29. Buchan AM, Lin CY, Choi J, Barber DL: Somatostatin, acting at receptor subtype 1, inhibits Rho activity, the assembly of actin stress fibers, and cell migration. J Biol Chem 2002; 277: 28431-28438. (Pubitemid 41079267)
30. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
31. Jackson LN, Chen LA, Larson SD, Silva SR, Rychahou PG, Boor PJ, Li J, Defreitas G, Stafford WL, Townsend CM Jr, Evers BM: Development and characterization of a novel in vivo model of carcinoid syndrome. Clin Cancer Res 2009; 15: 2747-2755.